US Stock MarketDetailed Quotes
ARTV Artiva Biotherapeutics
- 10.815
- +0.815+8.15%
Trading Aug 26 14:42 ET
251.79MMarket Cap-9699P/E (TTM)
10.980High10.030Low102.24KVolume10.020Open10.000Pre Close1.08MTurnover0.73%Turnover RatioLossP/E (Static)23.28MShares16.00052wk High-1.44P/B150.54MFloat Cap9.71052wk Low--Dividend TTM13.92MShs Float16.000Historical High--Div YieldTTM9.50%Amplitude9.710Historical Low10.533Avg Price1Lot Size
Artiva Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q1)Mar 31, 2021 | (FY)Dec 31, 2020 | (Q4)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -5.92%-15.09M | 6.69%-47.43M | -47.38%-14.24M | -232.13%-50.83M | -213.96%-9.66M | -13.02%-15.3M | -84.53%-6.91M | 8.48M | -13.54M | -3.74M |
| Net income from continuing operations | 16.47%-13.96M | 51.15%-28.72M | -37.88%-16.72M | 18.15%-58.79M | 71.62%-12.12M | -299.23%-71.83M | -92.08%-11.39M | ---42.72M | ---17.99M | ---5.93M |
| Operating gains losses | --268K | --707K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 1.56%587K | 95.68%2.27M | 246.11%578K | 366.94%1.16M | 421.88%167K | 239.73%248K | 540.91%141K | --32K | --73K | --22K |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | 6,773.74%18.55M | --0 | --18.55M | ---278K | ---136K |
| Change In working capital | -4,812.50%-3.02M | -631.51%-28.28M | -93.11%64K | -111.57%-3.87M | -97.11%929K | 666.70%33.41M | 23.72%2.69M | --32.15M | --4.36M | --2.18M |
| -Change in receivables | 104.26%35K | -2,064.91%-1.23M | -9.89%-822K | 87.82%-57K | -1,285.19%-748K | ---468K | --146K | ---54K | --0 | --0 |
| -Change in prepaid assets | -291.63%-936K | 167.54%516K | 72.14%-239K | -232.17%-764K | -167.29%-858K | 60.07%-230K | 719.35%768K | ---321K | ---576K | ---124K |
| -Change in payables and accrued expense | -411.22%-2.19M | -114.63%-1.32M | -77.83%704K | -111.85%-615K | 22.96%3.18M | 16.68%5.19M | 26.23%2.51M | --2.58M | --4.45M | --1.99M |
| -Change in other current assets | -6.06%31K | 214.88%139K | --33K | ---121K | ---- | --0 | ---- | ---- | --236K | ---- |
| -Change in other current liabilities | ---- | --0 | ---- | --74K | ---- | ---- | ---- | ---- | ---- | ---- |
| -Change in other working capital | -88.40%45K | -1,007.05%-26.38M | 160.53%388K | -108.24%-2.38M | -102.14%-641K | 11,514.46%28.92M | -1,106.85%-735K | --29.94M | --249K | --73K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -5.92%-15.09M | 6.69%-47.43M | -47.38%-14.24M | -232.13%-50.83M | -213.96%-9.66M | -13.02%-15.3M | -84.53%-6.91M | --8.48M | ---13.54M | ---3.74M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 625.35%9.78M | -312.37%-25.98M | -209.30%-1.86M | -265.37%-6.3M | -1,208.70%-602K | -507.04%-1.72M | -364.32%-1.12M | -46K | -284K | -241K |
| Net PPE purchase and sale | 99.03%-18K | 48.28%-3.26M | -209.30%-1.86M | -265.37%-6.3M | -1,208.70%-602K | -507.04%-1.72M | -364.32%-1.12M | ---46K | ---284K | ---241K |
| Net investment purchase and sale | --9.8M | ---22.72M | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 625.35%9.78M | -312.37%-25.98M | -209.30%-1.86M | -265.37%-6.3M | -1,208.70%-602K | -507.04%-1.72M | -364.32%-1.12M | ---46K | ---284K | ---241K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 2,029.67%24.39M | 96.07%-12K | -100.83%-1.26M | -100.20%-305K | 308.49%152.75M | 13.31%-241K | 153.98M | 37.4M | -278K |
| Net issuance payments of debt | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | --3M | --0 |
| Net common stock issuance | --0 | -140.00%-12K | ---12K | ---5K | ---- | --0 | ---- | ---- | --215K | ---- |
| Net preferred stock issuance | ---- | ---- | ---- | ---- | --0 | 346.35%154.61M | 200.00%1K | --154.62M | --34.64M | ---1K |
| Proceeds from stock option exercised by employees | ---- | 7,250.30%24.4M | ---- | 89.71%332K | 47.41%199K | --175K | --5K | --135K | ---- | ---- |
| Net other financing activities | ---- | ---- | ---- | 21.74%-1.59M | 34.63%-504K | -342.92%-2.03M | 24.00%-247K | ---771K | ---459K | ---325K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | 2,029.67%24.39M | 96.07%-12K | -100.83%-1.26M | -100.20%-305K | 308.49%152.75M | 13.31%-241K | --153.98M | --37.4M | ---278K |
| Net cash flow | ||||||||||
| Beginning cash position | -47.69%53.76M | -36.23%102.78M | -36.23%102.78M | 533.47%161.17M | 533.47%161.17M | 1,259.08%25.44M | 470.40%169.43M | --25.44M | --1.87M | --29.7M |
| Current changes in cash | 67.09%-5.3M | 16.06%-49.01M | -52.46%-16.12M | -143.02%-58.39M | -106.51%-10.57M | 475.84%135.73M | -93.92%-8.27M | --162.41M | --23.57M | ---4.26M |
| End cash Position | -44.08%48.46M | -47.69%53.76M | -42.46%86.66M | -36.23%102.78M | -19.83%150.6M | 533.47%161.17M | 533.47%161.17M | --187.86M | --25.44M | --25.44M |
| Free cash flow | 6.22%-15.1M | 11.27%-50.69M | -56.88%-16.11M | -235.49%-57.13M | -221.72%-10.27M | -23.17%-17.03M | -101.46%-8.02M | --8.43M | ---13.83M | ---3.98M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
